Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report

Secondary hyperparathyroidism (SHPT) in dialysis is common. A young man on chronic hemodialysis with SHPT developed pancytopenia with resistant anemia requiring transfusions. A bone marrow biopsy showed grade 3 fibrosis, depleted cellularity, osteosclerosis, and decreased myelopoiesis. He initiated...

Descripción completa

Detalles Bibliográficos
Autores principales: Panuccio, Vincenzo Antonio, Tripepi, Rocco, Postorino, Adele, Greve, Bruna, Sabattini, Elena, Oliva, Esther Natalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995371/
https://www.ncbi.nlm.nih.gov/pubmed/36910010
http://dx.doi.org/10.3389/fmed.2022.1050062
_version_ 1784902808267390976
author Panuccio, Vincenzo Antonio
Tripepi, Rocco
Postorino, Adele
Greve, Bruna
Sabattini, Elena
Oliva, Esther Natalie
author_facet Panuccio, Vincenzo Antonio
Tripepi, Rocco
Postorino, Adele
Greve, Bruna
Sabattini, Elena
Oliva, Esther Natalie
author_sort Panuccio, Vincenzo Antonio
collection PubMed
description Secondary hyperparathyroidism (SHPT) in dialysis is common. A young man on chronic hemodialysis with SHPT developed pancytopenia with resistant anemia requiring transfusions. A bone marrow biopsy showed grade 3 fibrosis, depleted cellularity, osteosclerosis, and decreased myelopoiesis. He initiated Etelcalcetide 7⋅5 mg 3 times weekly with improvement in SHPT concomitant with near normalization of blood counts. Marrow biopsy at 12 months showed clearance of marrow reticulin, improvement of osteosclerosis and normalization of bone trabeculae, cellularity and myelopoiesis. This is a unique case in which Etelcalcetide treatment is comparable to parathyroidectomy on SHPT and is associated with significant improvement in severe myelofibrosis.
format Online
Article
Text
id pubmed-9995371
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99953712023-03-10 Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report Panuccio, Vincenzo Antonio Tripepi, Rocco Postorino, Adele Greve, Bruna Sabattini, Elena Oliva, Esther Natalie Front Med (Lausanne) Medicine Secondary hyperparathyroidism (SHPT) in dialysis is common. A young man on chronic hemodialysis with SHPT developed pancytopenia with resistant anemia requiring transfusions. A bone marrow biopsy showed grade 3 fibrosis, depleted cellularity, osteosclerosis, and decreased myelopoiesis. He initiated Etelcalcetide 7⋅5 mg 3 times weekly with improvement in SHPT concomitant with near normalization of blood counts. Marrow biopsy at 12 months showed clearance of marrow reticulin, improvement of osteosclerosis and normalization of bone trabeculae, cellularity and myelopoiesis. This is a unique case in which Etelcalcetide treatment is comparable to parathyroidectomy on SHPT and is associated with significant improvement in severe myelofibrosis. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9995371/ /pubmed/36910010 http://dx.doi.org/10.3389/fmed.2022.1050062 Text en Copyright © 2023 Panuccio, Tripepi, Postorino, Greve, Sabattini and Oliva. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Panuccio, Vincenzo Antonio
Tripepi, Rocco
Postorino, Adele
Greve, Bruna
Sabattini, Elena
Oliva, Esther Natalie
Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
title Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
title_full Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
title_fullStr Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
title_full_unstemmed Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
title_short Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
title_sort does etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? a case report
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995371/
https://www.ncbi.nlm.nih.gov/pubmed/36910010
http://dx.doi.org/10.3389/fmed.2022.1050062
work_keys_str_mv AT panucciovincenzoantonio doesetelcalcetidereversemyelofibroticbonechangesduetohyperparathyroidismacasereport
AT tripepirocco doesetelcalcetidereversemyelofibroticbonechangesduetohyperparathyroidismacasereport
AT postorinoadele doesetelcalcetidereversemyelofibroticbonechangesduetohyperparathyroidismacasereport
AT grevebruna doesetelcalcetidereversemyelofibroticbonechangesduetohyperparathyroidismacasereport
AT sabattinielena doesetelcalcetidereversemyelofibroticbonechangesduetohyperparathyroidismacasereport
AT olivaesthernatalie doesetelcalcetidereversemyelofibroticbonechangesduetohyperparathyroidismacasereport

Ejemplares similares